We only have this paper's title and publication details.
Read it at the sourceCaptured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The teachable critical appraisal point is that high-risk does not guarantee greater benefit. The control arm event rates were highest in TRACK (12% per year) vs VOYAGER PAD (8% per year) and COMPASS (5% per year).”
“My reaction to the TRACK results is that they are somewhat disappointing but not entirely surprising. Patients with advanced CKD have among the highest CV event rates of any population, creating a strong rationale for testing antithrombotic strategies. However, advanced CKD is also characterized by an exceedingly high risk of bleeding that fundamentally alters the potential net clinical benefit. In the TRACK trial, low-dose rivaroxaban failed to demonstrate significant CV benefit coupled with increased major bleeding, and as such, cannot be recommended for CV protection in individuals with advanced CKD.”
“Clinical decisions regarding anticoagulation in people with advanced kidney disease should not be extrapolated from other cardiovascular populations. This trial underscores the need for dedicated cardiovascular outcome trials in people with advanced CKD.”
No takes yet. Share an insight, caveat, or question.
Paolo Coppi (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: